T-Cell Immunotherapies: The Goldrush Continues

Amidst the current initiatives to develop more targeted anti-cancer therapies, immunotherapy has emerged as a highly potent option to eradicate tumor cells with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. It encompasses several treatment approaches, such as monoclonal antibodies, immune checkpoint inhibitors, therapeutic vaccines, cytokine therapies and cell-based therapies. In recent years, adoptive T-Cell Immunotherapies has emerged as a potent and viable therapeutic intervention.


Social Media is Abuzz With the Growing Interest in T-Cell Immunotherapies

Exponential increase in the number of tweets on the social medial platform, Twitter, indicates the rising interest in the field of T-cell immunotherapy.


Opinions Solicited from Various Stakeholders Validate the Future Potential

The widening optimism, confirmed from several industry / academia stakeholders, is indicative of the lucrative future potential.


Both Industry and Non-Industry Players are Actively Contributing

The research landscape has steadily grown as several industry / non-industry players across the globe have made notable contributions to this field.


An Already Robust Pipeline Holds Significant Promise

Currently, a variety of candidates, primarily CAR-T products, are being evaluated across various stages of development

Around 75% of the T-cell immunotherapies are used to offer CAR-T Therapy wherein 136 are currently in discovery stage and majorly developed by industry players.

Several New Targets and Indications are Being Explored

Many novel, disease-specific targets have been discovered and are being explored for the treatment of a diverse range of oncological indications.


Key Opinion Leaders Continue to Play a Pivotal Role

A number of prominent scientists, acting as key opinion leaders, have led the clinical development efforts.


As Blockbusters Emerge, We Anticipate Over 80% Annualized Growth

With a promising development pipeline and encouraging clinical outcomes, the market is anticipated to witness significant growth in the coming decade

The T-cell immunotherapy market is fragmented across various segments and the market is anticipated to grow at 80% annualized growth by 2030

Realizing the Future Potential, Several CMOs have Surfaced to Cater to Increasing Demand

CMOs offering manufacturing services for different types of cell-based therapies have become an indispensable asset in this emerging market

Currently, around 40 T-cell therapy CMO are currently present in market. Majority of them are based in North America

Our Social Media Platform

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis